• Register
  • Login

European Journal of Molecular & Clinical Medicine

  1. Home
  2. Cross-sectional study to determine the prevalence of telogen effluvium among patients experiencing COVID-19 infection or vaccination in Saudi Arabia and Arabic countries

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

Journal Metrics

News

Cross-sectional study to determine the prevalence of telogen effluvium among patients experiencing COVID-19 infection or vaccination in Saudi Arabia and Arabic countries

    Author

    • Waleed Alsalhi, MD , Yazeed Almulhim, MBBS, Naiem T. Issa, MD, PhD
,

Document Type : Research Article

  • Article Information
  • Download
  • Export Citation
  • Statistics
  • Share

Abstract

Background: Telogen effluvium (TE) after COVID-19 infection or vaccination is a common sequelae in dermatology clinics.
Objective: to study the prevalence of telogen effluvium in COVID-19 patients and its association with COVID vaccine.
Methods: Cross-sectional study via online questionnaire in Saudi Arabia and other Arabic countries.
Results: Prevalence of hair loss among COVID-19 patients is ~85% with 45.9%  meeting the criteria of TE. Majority of those with high fever associated with COVID-19 developed TE (87.5%). 100% of hospitalized patients exhibited TE with 58% having diffuse hair loss for less than 6 months (acute TE) and 32% for more than 6 months (chronic TE). 63.2% of our participants had hair loss after COVID vaccination regardless of vaccine type with the majority experiencing it after the first dose (55.8%).
Limitations: The majority of the participants were female. Other factors associated with hair loss were taken into consideration.
Conclusions: COVID-19 infection and its vaccines carry a high risk for development of telogen effluvium.

Keywords

  • COVID-19
  • SAR-COV-2
  • Telogen effluvium
  • hair loss
  • vaccine
  • Saudi Arabia
  • COVID-19 Vaccination
  • Corona virus
  • Vaccine reactions
  • COVID19 vaccine
  • XML
  • PDF 534.25 K
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • VANCOUVER
    • Article View: 55
    • PDF Download: 104
European Journal of Molecular & Clinical Medicine
Volume 9, Issue 7
September 2022
Page 4663-4674
Files
  • XML
  • PDF 534.25 K
Share
Export Citation
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • VANCOUVER
Statistics
  • Article View: 55
  • PDF Download: 104

APA

PhD, W. A. M. ,. Y. A. M. N. T. I. M. (2022). Cross-sectional study to determine the prevalence of telogen effluvium among patients experiencing COVID-19 infection or vaccination in Saudi Arabia and Arabic countries. European Journal of Molecular & Clinical Medicine, 9(7), 4663-4674.

MLA

Waleed Alsalhi, MD , Yazeed Almulhim, MBBS, Naiem T. Issa, MD, PhD. "Cross-sectional study to determine the prevalence of telogen effluvium among patients experiencing COVID-19 infection or vaccination in Saudi Arabia and Arabic countries". European Journal of Molecular & Clinical Medicine, 9, 7, 2022, 4663-4674.

HARVARD

PhD, W. A. M. ,. Y. A. M. N. T. I. M. (2022). 'Cross-sectional study to determine the prevalence of telogen effluvium among patients experiencing COVID-19 infection or vaccination in Saudi Arabia and Arabic countries', European Journal of Molecular & Clinical Medicine, 9(7), pp. 4663-4674.

VANCOUVER

PhD, W. A. M. ,. Y. A. M. N. T. I. M. Cross-sectional study to determine the prevalence of telogen effluvium among patients experiencing COVID-19 infection or vaccination in Saudi Arabia and Arabic countries. European Journal of Molecular & Clinical Medicine, 2022; 9(7): 4663-4674.

  • Home
  • About Journal
  • Editorial Board
  • Submit Manuscript
  • Contact Us
  • Glossary
  • Sitemap

News

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

Newsletter Subscription

Subscribe to the journal newsletter and receive the latest news and updates

© Journal Management System. Powered by ejournalplus